Company
ixlayer
A Direct-to-Patient Platform Built for Biopharma
- Status
- Operatingas of 2026-09-22
- Business model
- B2B
- Customers
- Biopharma
- Legal name
- IX Layer Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
ixlayer’s unified direct-to-patient platform, helps biopharma transform the patient experience with integrated AI capabilities.
Funding snapshot
- Total raised
- $61.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $61.3M2021-02-24
Funding rounds
- Round, 2021
- $61.3M2021-02-24, SEC form D sold, 8 investors
Products
- Web
- Direct-to-Patient Platform
Loading relationship preview